Becker's Healthcare April 29, 2024
As some formularies begin to favor biosimilars, CVS Health and Cigna Group’s Evernorth are veering further into the biosimilar business, The Wall Street Journal reported April 29.
CVS replaced Humira — the all-time highest-grossing drug — with biosimilars from its main formularies April 1. A few weeks later, Evernorth Health Services announced a Humira biosimilar will be available for eligible patients in June.
The first Humira biosimilar launched in January 2023, but AbbVie’s autoimmune biologic retained its market influence because of the drugmaker’s high rebates for pharmacy benefit managers.
More...
Today's Sponsors
Today's Sponsor